King Wealth Management Group Sells 45,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

King Wealth Management Group decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 22.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 160,000 shares of the company’s stock after selling 45,000 shares during the period. King Wealth Management Group’s holdings in Teva Pharmaceutical Industries were worth $3,232,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth lifted its holdings in Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the period. Vanguard Personalized Indexing Management LLC boosted its stake in Teva Pharmaceutical Industries by 30.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 35,274 shares of the company’s stock valued at $591,000 after acquiring an additional 8,192 shares during the last quarter. CWM LLC lifted its stake in shares of Teva Pharmaceutical Industries by 18.1% in the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after purchasing an additional 767 shares during the period. Finally, MGO One Seven LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $236,000. 54.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TEVA shares. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, December 22nd. The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Jefferies Financial Group upped their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Scotiabank upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Finally, Bank of America lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.11.

Teva Pharmaceutical Industries Stock Up 1.2%

TEVA stock opened at $34.40 on Wednesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock’s 50 day simple moving average is $32.31 and its 200 day simple moving average is $24.81. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a market cap of $39.46 billion, a P/E ratio of 28.67, a price-to-earnings-growth ratio of 1.94 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the previous year, the business earned $0.71 EPS. The company’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director owned 367,600 shares in the company, valued at $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 422,060 shares of company stock valued at $12,254,965. 0.49% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.